Orphatech Pharmaceuticals, GmbH Report issue

For profit Phase 2
Founded: Niederkassel Germany (2008)
Status: Acquired by Alexion (2011) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial
2009
NCT00957749
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

Fosdenopterin (Nulibry) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Metal Metabolism, Inborn Errors (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1